Atrial fibrillation (AF) is self-perpetuating, via mechanisms of acute electrical remodelling and 'second factors' acting over a longer time course. Renin-angiotensin system (RAS) blockade may inhibit AF self-perpetuation. We evaluated the effects of RAS blockade with candesartan in a burst-paced goat model of lone AF in which both mechanisms are known to operate. Bioactivity of oral candesartan was demonstrated in 10 goats by inhibition of the pressor effect of angiotensin II. The effects of candesartan on electrical remodelling were assessed in 12 placebo and 12 candesartan-treated goats in a 28-day burst pacing protocol. To assess the effects of candesartan on second factors (structural remodelling), 16 goats underwent further 28-day periods of burst pacing (two periods in 16 goats, three periods in eight goats) each separated by periods of sinus rhythm sufficient for electrical remodelling to reverse. There was a progressive rise in angiotensin levels in both groups. Candesartan (0.5 mg/kg/day) achieved a 76% blunting of the pressor effect of angiotensin II and had no effect on electrical remodelling; the half time for fall of atrial effective refractory period (AERP) was 22.3 ± 4.9 h (placebo) and 22.0 ± 3.2 h (candesartan) (p = ns). Candesartan had no effect on AF stability, which progressively increased over successive 28-day periods (ANOVA p < 0.05). Candesartan had no effect on atrial electrical remodelling or the operation of 'second factors' in a goat model of lone AF. These findings suggest that any benefits of RAS blockade in patients with AF are unlikely to be due to direct effects on atrial remodelling.
Introduction
Atrial fibrillation (AF) is estimated to affect approximately 1% of the US population 1 and projections from census data suggest that this will increase by a further 40-50% within 15 years. 2 AF is associated with an approximate doubling of mortality, predominantly due to stroke and heart failure. 3 Current strategies towards AF management are less than satisfactory.
One potential novel target for therapy is the process of self-perpetuation of AF, thought to be caused in part by electrical remodelling. Atrial electrical remodelling refers to shortening and reversal of rate adaptation of the atrial effective refractory period (AERP), which occurs as a result of AF. 4 In animal models of AF the time course of electrical remodelling (48-72 h) differs from the time course of progression to persistent AF (approximately 7 days), suggesting additional or 'second' factors are operating in the self-perpetuating process. 4 Atrial structural changes or 'structural remodelling' occurring as a result of AF may underlie the operation of these second factors. 5 Todd et al. 6 showed that repeated 28-day periods of AF separated by periods of sinus rhythm sufficient for the electrical remodelling process to reverse led to a progressive increase in AF stability. This study demonstrated the contribution of a 'second factor' in the self-perpetuation of AF and provided a protocol that could provide further insight into its mechanism.
It has been hypothesised that antagonists of the renin angiotensin system (RAS) might retard or reverse atrial electrical and structural remodelling. 7 Antagonists of the RAS inhibit angiotensin IImediated intracellular calcium overload, 8 which is thought to be relevant to the remodelling process. They may also prevent angiotensin II-mediated myolysis, gap junction remodelling, and atrial fibrosis. 9 AF itself is a potent promoter of the atrial RAS, with the potential to lead to a positive feedback loop of further RAS activation and AF promotion.
Kumagai et al. 10 found that in a rapid atrially paced dog model of AF that blockade of the RAS with candesartan led to a shortening of induced AF Effects of angiotensin receptor blockade on atrial electrical remodelling and the 'second factor' in a goat burst-paced model of atrial fibrillation episodes. The underlying mechanism for this was thought to be a candesartan-mediated reduction in atrial fibrosis. However, it is unclear in this model whether the observed atrial fibrosis is due directly to AF or tachycardia-induced left ventricular dysfunction; indeed in an experiment examining the effects of iatrogenic atrioventricular (AV) block on atrial remodelling, more atrial fibrosis was observed with intact AV conduction than in the presence of AV block with ventricular pacing. 11 The Allessie goat model of AF 4 exhibits little intrinsic fibrosis even in the presence of intact AV conduction, 12 develops structural changes akin to those seen in idiopathic AF in man, and has lower ventricular rates during AF than the dog model. 4, 10 It is therefore ideally placed to determine the direct effects of RAS blockade on atrial electrical and structural remodelling. We tested the hypothesis that blockade of the renin-angiotensin system would ameliorate or inhibit atrial electrical remodelling and the operation of 'second factors' in a goat model of idiopathic AF. We also examined the effects of cumulative 28-day periods of atrial fibrillation on circulating angiotensin levels and on left ventricular function.
Materials and methods
All experiments were conducted in accordance with a project license issued by the UK Home Office under the Animals (Scientific Procedures) Act 1986. The animals were allowed free access to food and water and were unrestrained in their pens throughout the experiments.
Assessment of biological activity of candesartan
Oral bioactivity of candesartan was examined in 10 adult female goats (mean weight ± SD, 72.9 ± 13 kg) ( Figure 1 ). General anaesthesia was induced and maintained using 5 mg midazolam and 4% isoflurane in a 2: 1 mixture of oxygen and nitrous oxide. The goats were intubated and allowed to breathe spontaneously. The external jugular vein was cannulated with a 6F haemostatic sheath. An 18-gauge arterial cannula was sited in an antecubital artery and arterial blood pressure continuously monitored using a transducer set and pressure monitor. A solution of angiotensin II in 0.9% saline was infused via the external jugular vein at doses of up to 40 ng/kg/min. Three blood pressure recordings (30 s apart) were taken at baseline and after 5 min at each infusion rate. The goats were allowed to recover from general anaesthesia.
From the following day, candesartan cilexetil (Takeda, Japan) suspended in a solution of 0.5% carboxymethylcellulose was administered orally for 7 days at doses of 0.1 mg/kg/day (n = 2), 0.2 mg/kg/day (n = 2) and 0.5 mg/kg/day (n = 6). The angiotensin infusion protocol ( Figure 1 ) was then repeated under general anaesthesia.
Effect of candesartan on electrical remodelling
Twenty-eight goats (mean weight, 65.1 ± 10 kg) each had two pacing systems implanted. General anaesthesia was induced and maintained as above. An incision was made on the right lateral aspect of the neck to expose the right external jugular vein.
Figure 1
Angiotensin infusion protocol used in biological assay of candesartan. Angiotensin II was infused at increasing doses and the pressor response measured. Following recovery from anaesthesia, goats received oral candesartan at a dose of 0.1 mg/kg/day (n = 2), 0.2 mg/kg/day (n = 2) and 0.5 mg/kg/day (n = 6) for 7 days. The angiotensin infusion protocol was then repeated. A small venotomy was made and two active-fixation bipolar steroid-eluting leads positioned in the right atrial appendage and one active-fixation bipolar steroid-eluting lead in the right ventricular apex under fluoroscopic guidance. One atrial lead was connected to an pacemaker capable of delivering short-coupled atrial extrastimuli (Cosmos II, Intermedics Inc.) and the remaining atrial and ventricular lead to a pacemaker with a software patch enabling burst pacing (Thera or AT501, Medtronic Inc.). The wound was closed and goats allowed to recover from general anaesthesia.
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Following pacemaker implanation the animals were allowed to recover for 14 days. Twelve goats received via oral syringe candesartan cilexitil (Takeda, Japan) suspended in a solution of 0.5% carboxymethylcelluluse at a dose of 0.5mg/kg/day and 12 goats received 0.5% carboxymethyl cellulose only, commencing 7 days prior to and continuing throughout the period of burst pacing. The goats then underwent repetitive reinduction of AF for a 4-week period. The pacing system automatically delivered a 2 second burst at 50Hz at 4 times diastolic threshold via the right atrial lead when two beats of sinus rhythm were detected. Burst pacing was inhibited when AF was detected.
At intervals as illustrated in Figure 2 , measurements were made of AERP, inducibility of AF by extrastimulus pacing, AF stability (mean duration of individual AF episodes), and atrial and ventricular cycle length.
In order to measure AERP, one pacemaker was used to deliver extrastimulus pacing at basic pacing drive cycle lengths of 400, 350, 300, 250 and 200 ms. The intracardiac atrial electrogram was telemetered in real-time using the second pacemaker and used to establish whether atrial capture had occurred. AERP was measured using a drive train of eight extrastimuli (S 1 ) followed by a single S 2 , all at four times diastolic threshold. The initial S 1 -S 2 coupling interval was begun at a shorter interval than the expected AERP and increased incrementally in 10 ms steps until atrial capture occurred. The AERP was defined as the longest S 1 -S 2 that failed to capture the atrium and was taken as the mean of three measurements.
At the time of AERP measurement, the presence or absence of AF induced as a response to the shortest coupling interval resulting in atrial capture was recorded. AF was considered inducible if atrial capture was followed by rapid atrial activity lasting at least one second on at least two of three attempts.
The duration of induced episodes of AF was determined by direct telemetry of the endocardial atrial signal recorded by the pacing system via the pacemaker programmer and by the log stored, which contained the number and time of burst pacing episodes.
Effect of candesartan on the operation of 'second factors'
We assessed the effects of candesartan on the 'second factor' using the protocol originally described by Todd et al. 6 in which the operation and time course of second factors are well characterised. In this protocol, 28-day periods of burst pacing are separated by periods during which electrical remodelling is allowed to reverse completely ( Figure 3 ). Any cumulative increase in AF stability with successive 28-day periods in this model is interpreted as being due to the operation of second factors. Sixteen of the goats (eight candesartan, eight placebo) used in the electrical remodelling protocol described above underwent direct current (DC) cardioversion under general anaesthetic after the initial 28-day period of burst pacing. Electrical remodelling was allowed to reverse; AERP was measured daily until it recovered to within 5% of baseline, at which time a second 28-day period of AF reinduction commenced. Eight of the 16 goats (four candesartan, four placebos) underwent a third 28-day period of AF reinduction following cardioversion and reversal of electrical remodelling ( Figure 3 ).
During burst pacing, measurements were made of AERP inducibility of AF, AF stability and atrial and ventricular cycle length as described above.
Measurement of circulating angiotensin II levels
Angiotensin II assay was undertaken during each 28-day period in candesartan, placebo and control animals. Samples of venous blood were drawn by direct venepuncture from the left internal jugular vein. Samples were taken at 0, 4, 8, 12, and 24 h, daily until 1 week and once weekly until the end of each 28-day period. 7 ml samples were transferred into EDTA vacutainers and immediately centrifuged at 5000 rpm for 15 min at 4°C. The supernatant plasma was stored at -70°C pending analysis. The time from venepuncture to storage was less than 30 min in all cases. A validated assay was used to measure angiotensin II levels. 13
Measurement of left ventricular function
After DC cardioversion, animals scheduled for sacrifice were maintained under general anaesthesia. An incision was made over the right side of the sternum and the costochondral joints divided, opening the right pleural cavity. At this point, mechanical ventilation was commenced. The right lung was allowed to deflate, exposing the rightsided pericardium.
Echocardiography was undertaken by placing the probe directly on the pericardium, allowing views approximating to a parasternal long and short axis. The technique of epicardial echocardiography is well validated in animal models of cardiac disease. 14 Left ventricular ejection fraction was calculated by a blinded operator from shortaxis measurements taken at the level of the papillary muscles. Measurements of left ventricular function were made in control animals and in candesartan and placebo treated animals after three 28-day periods of burst pacing.
Statistical analysis was carried out using Prism 4.0 for Macintosh. Data are expressed as mean ± standard deviation. Changes in refractory period were compared using the half time of the AERP. This was defined as the time taken for the AERP to fall to half of the difference between baseline and nadir. 6 Paired data were analysed by use of a paired t-test for parametric data and by Wilcoxon's log-rank test for non-parametric data. Unpaired data were analysed by use of an unpaired t-test for parametric data and the Mann-Whitney U-test for non-parametric data. Multiple data sets were compared using one-way analysis of variance (ANOVA). A two-tailed value of < 0.05 was considered statistically significant.
Results

Assessment of biological activity of candesartan
Angiotensin II infusion alone caused a dosedependent increase in blood pressure. At an infusion rate of 40 ng/kg/min the mean increase in systolic blood pressure from baseline was 34.0 ± 1.9 mmHg, in diastolic blood pressure There was no significant fall in baseline systolic blood pressure after 7 days of oral candesartan (baseline 108.5 ± 2.9 mmHg, 104.4 ± 2.9 mmHg after 1 week [p = ns]).
Administration of oral candesartan led to a dosedependent blunting of the pressor response to angiotensin infusion (Figure 4) . At a dose of 0.5 mg/kg/day the angiotensin II-mediated increase in systolic blood pressure was reduced from 34.1 ± 1.9 mmHg to 8.2 ± 3.2 mmHg (p = 0.0015). Similar changes were seen in diastolic blood pressure with blunting of the maximum pressor effect from 28.6 ± 10.3 mmHg to 11.9 ± 8.1 mmHg (p = 0.0013) and in mean blood pressure from 28.1 ± 7.7 to 10.9 ± 7.3 mmHg (p = 0.0011). One-way ANOVA analysis of the data was consistent with a significant dosedependent effect of candesartan on systolic (p = 0.05), diastolic (p = 0.029) and mean (p = 0.029) blood pressures.
A dose of 0.5 mg/kg/day achieved a 76% blunting of the pressor response to infused angiotensin II; this was felt to reflect significant angiotensin receptor blockade and this dose was used in subsequent experiments. The calculated dose for a 60 kg animal (30 mg/day) compares with the maximum licensed dose in man of 32 mg/day.
Effect of candesartan on electrical remodelling and AF stability during the first 28-day period of burst pacing
Candesartan had no effect on the baseline atrial refractory period at any drive cycle length. Prior to the initiation of burst pacing, AERP at a drive cycle length of 400 ms was 170.0 ± 9.3 ms prior to candesartan administration and 169.2 ± 10.6 ms after 1 week of oral candesartan (p = ns).
Shortening of AERP
Burst pacing led to a progressive fall in atrial refractory period in both placebo and candesartan groups ( Figure 5, upper panel) . In all goats, the refractory period reached a nadir within 120 h and did not fall significantly after this.
Candesartan had no effect on the rate or degree of fall in AERP. After 72 h, AERP at a drive cycle length of 400 ms had fallen from 165.8 ± 10.5 ms to 85.8 ± 11.4 ms in the placebo group and from 169.2 ± 10.6 ms to 84.2 ± 6.5 ms in the candesartan group (p = ns). The half time for the placebo group was 22.3 ± 4.9 h and for the candesartan group 22.0 ± 3.2 h (p = ns).
Rate adaptation of AERP
At baseline there was progressive rate adaptation of the refractory period from 165.8 ± 10.5 ms at a drive cycle length of 400 ms to 140.0 ± 6.7 ms at a drive cycle length of 200 ms in the placebo group, and from 169.2 ± 10.6 ms at 400 ms to 145.0 ± 17.8 ms at 200 ms in the candesartan group. AERP measurements were possible in all animals at all drive cycle lengths at baseline and 12 h. After this period, AERP measurements were possible in only six of 12 placebos and seven of 12 candesartan animals at drive cycle lengths shorter than 300 ms due to the induction of prolonged AF by measurement of AERP at longer drive cycle lengths.
There was no significant difference in rate adaptation between placebo and candesartan groups. After 48 h there was reversal of normal rate adaptation in the placebo group. At a drive cycle length of 400 ms AERP was 97.5 ± 50.6 ms, rising to 105.0 ± 17.8 ms at a drive cycle length of 200 ms. Reversal of rate adaptation after 48 h was also observed in the candesartan group, with an AERP at 400 ms of 85.0 ± 27.2 ms rising to 112.5 ± 43.4 ms at 200 ms.
Other electrophysiological parameters AF cycle length (AFCL) shortened progressively with increasing duration of AF (Table 1) . There was no difference in the rate or degree of fall between candesartan and placebo groups.
Ventricular cycle length (VCL) during AF remained constant throughout the 28-day period ( Table 2 ). There were no significant differences between placebo and candesartan groups.
AF inducibility and stability
AF became increasingly inducible during non-invasive programmed stimulation (NIPS) with increasing duration of burst pacing. One goat in the placebo group and two in the candesartan group had transient AF inducible by single short-coupled extrastimuli prior to burst pacing. After 48 h of burst pacing, 80-90% of goats had inducible AF and after 2 weeks of burst pacing, all goats had inducible AF. There was no difference in AF inducibility between placebo and candesartan groups; after 48 h 10 of 12 goats in the placebo group and 11 of 12 goats in the candesartan group had inducible AF (p = ns).
Induced AF stability, as evidenced by progressively longer induced AF duration, increased with throughout the 28-day protocol. After 1 week, six of the 12 animals in each group were in persistent AF. There was no difference in the increase in AF stability between candesartan-and placebo-treated animals ( Figure 6 ).
Effect of candesartan on operation of 'second factors' Cumulative effects of successive 28-day periods of burst pacing on AF stability
Placebo-treated goats showed a significant cumulative increase in AF stability with successive 28-day periods of burst pacing (ANOVA p = 0.05). Goats treated with oral candesartan showed an almost identical pattern of increasing AF stability with no evidence of an attenuating or inhibitory effect (p = ns compared with placebo) ( Figure 6 ). Cumulative effects of successive 28-day periods of burst pacing on electrical remodelling There was no difference in the degree or rate of fall in AERP (electrical remodelling) within or between candesartan and placebo groups with successive Paper SAGE Publications 2010 Los Angeles, London, New Delhi and Singapore 28-day periods of burst pacing ( Figure 5 ). In all goats, electrical remodelling was complete (as evidenced by a fall in AERP from baseline to nadir) within 120 h. Reversal of electrical remodelling occurred within 7 days of cardioversion in all goats.
Cumulative effects of successive 28-day periods of burst pacing on other electrophysiological parameters
AF cycle length returned to baseline after reversal of electrical remodelling in both groups. There was no cumulative effect of successive 28-day episodes of AF on the rate or degree of shortening of AFCL (Table 1) .
Ventricular cycle length (VCL) during episodes of AF remained constant throughout the three 28-day periods in both groups ( Table 2 ). There were no statistically significant differences within or between placebo and candesartan groups at any time.
Effects of successive 28-day periods of burst pacing and treatment with candesartan on circulating angiotensin II levels
There were no significant changes in circulating angiotensin II levels in control animals.
In the placebo group there was a progressive rise in circulating angiotensin II levels during each successive 28-day period of burst pacing (Figure 7) . After the first 28-day period, levels had risen to 90.5 ± 21.1% compared with the baseline measurement prior to the initiation of burst pacing (p < 0.0001), with further increases to 105.4 ± 26.8% ( p < 0.0001) compared with baseline after the second 28-day period and 124.0 ± 23.7% (p = 0.016) after the third 28-day period.
In the candesartan group there were increases in circulating angiotensin II levels during each successive 28-day period (Figure 7) . After the first 28-day period, levels had risen to 95.6 ± 24.2% compared with the baseline measurement (p < 0.0001), after the second 28-day period levels had risen to 79.3 ± 49.9% (p = 0.006) and after the third 28-day period to 103.0 ± 27.7% (p = 0.016). There were no significant differences in circulating angiotensin II levels between placeboand candesartan-treated animals.
Effects of successive 28-day periods of burst pacing and treatment with candesartan on left ventricular function
Successive 28-day periods of burst pacing and treatment with candesartan had no effect on left In control animals left ventricular ejection fraction (LVEF) was 53.8 ± 6.1%. After three 28-day periods of burst pacing, LVEF was 57.5 ± 16.1% in placebo-treated animals (p = ns) and 54.3 ± 11.7% in candesartan treated animals (p = ns).
Discussion
The principal novel findings of this study are:
The angiotensin receptor blocker (ARB)
candesartan is absorbed orally in the goat and has biological activity at the angiotensin I (AT1) receptor. 2. Successive 28-day periods of atrial burst pacing and treatment with candesartan have no effect on left ventricular function in this model. 3. Circulating angiotensin levels rise in a progressive manner with successive 28-day periods of burst pacing in both placebo-and candesartan-treated animals, with no difference between the two groups. 4. Despite evidence of activation of the RAS by burst pacing and evidence that the AT1 receptor is inhibited by oral candesartan in the goat, treatment with candesartan has no effect on atrial electrical remodelling, increases in AF stability due to 'second factors' or on any other electrophysiological parameter in the goat model of lone AF.
Previous studies have shown diverse and conflicting effects of angiotensin receptor blockade or angiotensin converting enzyme (ACE) inhibition on atrial electrical remodelling, AF self-perpetuation and atrial structural changes occurring because of AF. 10, [15] [16] [17] [18] Short-term studies with rapid atrial pacing lasting from 3 h to 3 days have suggested a protective effect of angiotensin receptor blockade with ACE or ARB on acute electrical remodelling in a canine rapid atrial pacing (RAP) model. Nakashima et al. 18 showed that after 3 h of RAP at 800bpm in the absence of AV block, intravenous candesartan and captopril completely inhibited AERP shortening and reversal of rate adaptation. SanMillan et al. 15 demonstrated that over 3 days of RAP at 400 bpm in the absence of AV block, enalapril (mode of administration not stated) completely attenuated the usual AERP shortening caused by RAP. The effect of RAP on ventricular rate was not reported.
Longer-term studies suggest that this short-term electrophysiological effect is not sustained. Shinagawa et al. 17 carried out a longer term study over 7 days in a dog RAP model in the presence of iatrogenic AV block. This showed no effect of oral enalapril on AF duration, AERP or AF vulnerability, or conduction velocity. The authors argued that the apparent short-term protection noted in the previous studies is not sustained. Kumagai et al. 10 examined the effects of the ARB candesartan administered orally in a dog RAP model without AV block over 5 weeks. They found no differences in AERP shortening, rate adaptation or AF cycle length, but in apparent conflict with Shinagawa's study, AF duration was significantly longer in controls than in candesartan-treated animals. Atrial conduction time was substantially longer in controls compared with candesartan and histological examination of the atria showed more fibrosis in controls than in the candesartan-treated animals. The authors argue that candesartan attenuates AF inducibility by prevention of the development of conduction slowing, presumably due to fibrosis.
There are alternative explanations for these findings, however. The authors concede that the ventricular rate in many dogs was greater than 200 bpm and that there may have been an element of tachycardia-induced left ventricular dysfunction, which was improved by candesartan. The dose of candesartan used in this study (10 mg/kg) was considerably higher than an equivalent human oral dose (licensed up to 32 mg/day).
In keeping with results described by Kumagai et al. 10 and Shinagawa et al, 17 , we found no effect of RAS blockade on electrical remodelling. In contrast with Kumagai's work, we found no effect on AF stability.
A more recent study was reported by Anne et al. in a rapidly atrially paced sheep model of AF. 19 Groups of animals with and without His bundle ablation were treated with a combination of the ACE inhibitor quinapril and the ARB losartan or placebo and underwent 12 weeks continuous rapid atrial pacing. There was no effect of angiotensin receptor blockade on electrical remodelling in either group. The time taken to develop persistent AF was slightly shorter in placebo-treated animals without His bundle ablation than in those with His bundle ablation. Angiotensin receptor blockade appeared to have a modest but statistically significant effect on the time taken to develop persistent AF in animals with intact AV conduction. The effects of rapid atrial pacing on left ventricular function were not reported, and so it is unclear whether the effects seen on the time to develop persistent AF in animals with intact AV conduction were due to antiremodelling effects or improvement in heart failure.
Clinical studies show that the greatest benefit of RAS blockade is in those patients with structural heart disease. 20 Madrid et al. 7 found that in unselected patients undergoing cardioversion, irbesartan at a dose of 150 mg daily led to a 69% reduction in AF recurrence. In a subsequent study of patients in whom significant structural heart disease or hypertension had been excluded, this dose was ineffective. 21 Interestingly a higher dose of 300 mg daily led to a smaller but statistically significant reduction in AF recurrence; however the numbers of patients randomised to the higher dose (30) was small.
The most promising results in clinical studies have been in patients with significant left ventricular dysfunction. Retrospective analyses of the TRACE 20 and SOLVD 22 studies showed significant reductions in AF incidence in the active treatment groups. Conversely, a recently published prospective, randomised study by the GISSI-AF group failed to show any beneficial effect of angiotensin receptor blockade with valsartan on time to first recurrence of AF in a patient population with less severe structural heart disease. 23 This patient
Figure 7
Effects of successive 28-day periods of burst pacing on circulating angiotensin II levels. population was predominantly comprised of those with hypertension with a relatively small contribution from heart failure or other structural heart disease. Our findings are in keeping with the observation that the most benefit is seen in the presence of left ventricular dysfunction, a feature which is absent in the goat model.
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Atrial fibrosis is prominent in patients with AF occurring in the setting of structural heart disease, but minimal or absent in patients with idiopathic AF. 5 Even with prolonged atrial fibrillation, significant fibrosis or apoptosis are not seen in the goat model. 5 The benefit of RAS blockade is readily apparent in patients with structural heart disease and in animal models which exhibit atrial fibrosis, but absent or difficult to detect in patients with lone AF and in the goat model.
Conclusions
The present study shows that, despite activation of the renin angiotensin system, angiotensin receptor blockade with candesartan does not prevent the self-perpetuating process in a model of lone AF. This observation is in keeping with the finding of Madrid et al. that angiotensin receptor blockade appears much less effective at maintaining sinus rhythm following cardioversion from AF in patients with lone AF 21 than in a population with a significant incidence of structural heart disease. 7 The lack of effect of angiotensin receptor blockade in a model which undergoes similar changes during electrical and structural remodelling 4, 5 to that seen in lone AF in man 24 supports the hypothesis that any beneficial effects of RAS blockade are more likely to be due to positive effects on left ventricular function and improvements in underlying disease processes rather than a direct antiremodelling effect.
